Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

The north-south and east-west gradient in colorectal cancer risk: a look at the distribution of modifiable risk factors and incidence across Canada.

Tung J, Politis CE, Chadder J, Han J, Niu J, Fung S, Rahal R, Earle CC.

Curr Oncol. 2018 Jun;25(3):231-235. doi: 10.3747/co.25.4071. Epub 2018 Jun 28.

2.

Measuring patient-reported outcomes to improve cancer care in Canada: an analysis of provincial survey data.

Tran K, Zomer S, Chadder J, Earle C, Fung S, Liu J, Louzado C, Rahal R, Moxam RS, Green E.

Curr Oncol. 2018 Apr;25(2):176-179. doi: 10.3747/co.25.3995. Epub 2018 Apr 30.

3.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK.

Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.

PMID:
29657135
4.

The experience of patients with cancer during diagnosis and treatment planning: a descriptive study of Canadian survey results.

Coronado AC, Tran K, Chadder J, Niu J, Fung S, Louzado C, Rahal R; Collaboration with the System Performance Steering Committee and the Technical Working Group.

Curr Oncol. 2017 Oct;24(5):332-337. doi: 10.3747/co.24.3782. Epub 2017 Oct 25.

5.

Acute care hospitalization near the end of life for cancer patients who die in hospital in Canada.

DeCaria K, Dudgeon D, Green E, Shaw Moxam R, Rahal R, Niu J, Bryant H.

Curr Oncol. 2017 Aug;24(4):256-261. doi: 10.3747/co.24.3704. Epub 2017 Aug 31.

6.

Complete axillary dissection without drainage for the surgical treatment of breast cancer: a randomized clinical trial.

Freitas-Junior R, Ribeiro LFJ, Moreira MAR, Queiroz GS, Esperidião MD, Silva MAC, Pereira RJ, Zampronha RAC, Rahal RMS, Soares LR, Dos Santos DL, Thomazini MV, de Faria CFS, Paulinelli RR.

Clinics (Sao Paulo). 2017 Jul;72(7):426-431. doi: 10.6061/clinics/2017(07)07.

7.

Choosing wisely in cancer control across Canada-a set of baseline indicators.

Tran K, Rahal R, Fung S, Lockwood G, Louzado C, Xu J, Bryant H.

Curr Oncol. 2017 Jun;24(3):201-206. doi: 10.3747/co.24.3643. Epub 2017 Jun 27.

8.

How different is cancer control across Canada? Comparing performance indicators for prevention, screening, diagnosis, and treatment.

Rahal R, Chadder J, DeCaria K, Lockwood G, Bryant H; System Performance Steering Committee and the Technical Working Group.

Curr Oncol. 2017 Apr;24(2):124-128. doi: 10.3747/co.24.3578. Epub 2017 Apr 27.

9.

Registered Replication Report: Rand, Greene, and Nowak (2012).

Bouwmeester S, Verkoeijen PPJL, Aczel B, Barbosa F, Bègue L, Brañas-Garza P, Chmura TGH, Cornelissen G, Døssing FS, Espín AM, Evans AM, Ferreira-Santos F, Fiedler S, Flegr J, Ghaffari M, Glöckner A, Goeschl T, Guo L, Hauser OP, Hernan-Gonzalez R, Herrero A, Horne Z, Houdek P, Johannesson M, Koppel L, Kujal P, Laine T, Lohse J, Martins EC, Mauro C, Mischkowski D, Mukherjee S, Myrseth KOR, Navarro-Martínez D, Neal TMS, Novakova J, Pagà R, Paiva TO, Palfi B, Piovesan M, Rahal RM, Salomon E, Srinivasan N, Srivastava A, Szaszi B, Szollosi A, Thor KØ, Tinghög G, Trueblood JS, Van Bavel JJ, van 't Veer AE, Västfjäll D, Warner M, Wengström E, Wills J, Wollbrant CE.

Perspect Psychol Sci. 2017 May;12(3):527-542. doi: 10.1177/1745691617693624. Epub 2017 Mar 1.

10.

A prospective randomized trial comparing patent blue and methylene blue for the detection of the sentinel lymph node in breast cancer patients.

Paulinelli RR, Freitas-Junior R, Rahal RM, Oliveira LF, Vilela MH, Moreira MA, Alves KL, Peleja MB, Resende TC.

Rev Assoc Med Bras (1992). 2017 Feb;63(2):118-123. doi: 10.1590/1806-9282.63.02.118.

11.

Mesenchymal Stem Cells in the Treatment of Traumatic Brain Injury.

Hasan A, Deeb G, Rahal R, Atwi K, Mondello S, Marei HE, Gali A, Sleiman E.

Front Neurol. 2017 Feb 20;8:28. doi: 10.3389/fneur.2017.00028. eCollection 2017. Review.

12.

Trends in breast cancer surgery at Brazil's public health system.

Freitas-Júnior R, Gagliato DM, Moura Filho JWC, Gouveia PA, Rahal RMS, Paulinelli RR, Oliveira LFP, Freitas PF, Martins E, Urban C, Lucena CÊM.

J Surg Oncol. 2017 Apr;115(5):544-549. doi: 10.1002/jso.24572. Epub 2017 Feb 6.

PMID:
28168857
13.

Analysis of Protein-Protein Interactions Between MEN Components.

Rahal R.

Methods Mol Biol. 2017;1505:81-88.

PMID:
27826858
14.

Contribution of the Unified Health Care System to mammography screening in Brazil, 2013.

Freitas-Junior R, Rodrigues DC, Corrêa RD, Peixoto JE, de Oliveira HV, Rahal RM.

Radiol Bras. 2016 Sep-Oct;49(5):305-310.

15.

Use of low-value radiotherapy practices in Canada: an analysis of provincial cancer registry data.

Tran K, Rahal R, Brundage M, Fung S, Louzado C, Milosevic M, Xu J, Bryant H; System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2016 Oct;23(5):351-355. Epub 2016 Oct 25.

16.

Smoking behaviours of current cancer patients in Canada.

Liu J, Chadder J, Fung S, Lockwood G, Rahal R, Halligan M, Mowat D, Bryant H.

Curr Oncol. 2016 Jun;23(3):201-3. doi: 10.3747/co.23.3180. Epub 2016 Jun 9.

17.

Sociodemographic and clinical factors affecting body image, sexual function and sexual satisfaction in women with breast cancer.

de Morais FD, Freitas-Junior R, Rahal RM, Gonzaga CM.

J Clin Nurs. 2016 Jun;25(11-12):1557-65. doi: 10.1111/jocn.13125. Epub 2016 Jan 27.

PMID:
27139170
18.

Patterns of care and treatment trends for Canadian men with localized low-risk prostate cancer: an analysis of provincial cancer registry data.

Tran K, Rahal R, Fung S, Louzado C, Porter G, Xu J, Bryant H; Collaboration with the System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2016 Feb;23(1):56-9. doi: 10.3747/co.23.3011. Epub 2016 Feb 18.

19.

Treatment patterns among Canadian men diagnosed with localized low-risk prostate cancer.

Sandoval C, Tran K, Rahal R, Porter G, Fung S, Louzado C, Liu J, Bryant H; System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2015 Dec;22(6):427-9. doi: 10.3747/co.22.2895.

20.

Wait times for prostate cancer treatment and patient perceptions of care in Canada: a mixed-methods report.

Tran K, Sandoval C, Rahal R, Porter G, Siemens R, Hernandez J, Fung S, Louzado C, Liu J, Bryant H; Collaboration with the System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2015 Oct;22(5):361-4. doi: 10.3747/co.22.2795.

21.

Recommendations on screening for cognitive impairment in older adults.

Pottie K, Rahal R, Jaramillo A, Birtwhistle R, Thombs BD, Singh H, Connor Gorber S, Dunfield L, Shane A, Bacchus M, Bell N, Tonelli M; Canadian Task Force on Preventive Health Care.

CMAJ. 2016 Jan 5;188(1):37-46. doi: 10.1503/cmaj.141165. Epub 2015 Nov 30. No abstract available.

22.

Targeting cancer with kinase inhibitors.

Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP.

J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1. Review.

23.

Rectal cancer resection and circumferential margin rates in Canada: a population-based study.

DeCaria K, Rahal R, Niu J, Lockwood G, Bryant H; System Performance Steering Committee and the Technical Working Group.

Curr Oncol. 2015 Feb;22(1):60-3. doi: 10.3747/co.22.2391. No abstract available.

24.

Use of pet in the management of non-small-cell lung cancer in Canada.

Vorauer E, Louzado C, DeCaria K, Hernandez J, Rahal R, Niu J, Lockwood G, Bryant H; Canadian Partnership Against Cancer System Performance Steering Committee and Technical Working Group, the Clinical pet Expert Panel, and provincial pet programs and cancer agencies.

Curr Oncol. 2014 Dec;21(6):337-9. doi: 10.3747/co.21.2271. No abstract available.

25.

Balance ability measured with the Berg balance scale: a determinant of fall history in community-dwelling adults with leg amputation.

Wong CK, Chen CC, Blackwell WM, Rahal RT, Benoy SA.

J Rehabil Med. 2015 Jan;47(1):80-6. doi: 10.2340/16501977-1882.

26.

Adjuvant and neoadjuvant treatment for rectal cancer, colon cancer, and non-small-cell lung cancer in older patients.

Rahal R, Porter G, Forte T, Fung S, Bryant H; Collaboration with the System Performance Steering Committee and the Technical Working Group.

Curr Oncol. 2014 Aug;21(4):193-5. doi: 10.3747/co.21.2109. No abstract available.

27.

Rates of breast cancer surgery in Canada from 2007/08 to 2009/10: retrospective cohort study.

Porter G, Wagar B, Bryant H, Hewitt M, Wai E, Dabbs K, McFarlane A, Rahal R.

CMAJ Open. 2014 Jun 17;2(2):E102-8. doi: 10.9778/cmajo.20130025. eCollection 2014 Apr.

28.

Two indicators of hospital resource efficiency in cancer care.

Rahal R, Xu J, Fung S, Bryant H; System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2014 Jun;21(3):144-6. doi: 10.3747/co.21.2022. No abstract available.

29.

Geographic disparities in surgery for breast and rectal cancer in Canada.

Forte T, Porter G, Rahal R, Decaria K, Niu J, Bryant H; System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2014 Apr;21(2):97-9. doi: 10.3747/co.21.1936. No abstract available.

30.

Examining cancer-risk profiles for the largest metropolitan areas across Canada.

Decaria K, Rahal R, Forte T, Lockwood G, Xu J, Bryant H; System Performance Steering Committee and Technical Working Group.

Curr Oncol. 2014 Feb;21(1):51-3. doi: 10.3747/co.21.1853. No abstract available.

31.

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, Haas K, Jaskelioff M, Wilson BG, Meyer MJ, Saenz-Vash V, Zhai H, Myer VE, Porter JA, Keen N, McLaughlin ME, Mickanin C, Roberts CW, Stegmeier F, Jagani Z.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3128-33. doi: 10.1073/pnas.1316793111. Epub 2014 Feb 11.

32.

Role of balance ability and confidence in prosthetic use for mobility of people with lower-limb loss.

Wong CK, Chen CC, Benoy SA, Rahal RT, Blackwell WM.

J Rehabil Res Dev. 2014;51(9):1353-64. doi: 10.1682/JRRD.2013.11.0235.

33.

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F.

Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.

PMID:
24362935
34.

Provincial rates and time trends in pancreatic cancer outcomes.

Fung S, Forte T, Rahal R, Niu J, Bryant H.

Curr Oncol. 2013 Oct;20(5):279-81. doi: 10.3747/co.20.1672. No abstract available.

35.

The value of collecting population-based cancer stage data to support decision-making at organizational, regional and population levels.

Brierley JD, Srigley JR, Yurcan M, Li B, Rahal R, Ross J, King MJ, Sherar M, Skinner R, Sawka C.

Healthc Q. 2013;16(3):27-33.

PMID:
24034774
36.

Temporal variation of breast cancer surgical treatment in a university hospital in Brazil's Central West region.

Freitas R Jr, Siqueira LB, Carrijo EN, Lacerda RP, Paulinelli RR, Rahal RM, Oliveira LF.

Rev Col Bras Cir. 2013 May-Jun;40(3):180-5. English, Portuguese.

37.

Measuring concordance with guidelines for the diagnosis and treatment of colon cancer.

Rahal R, Klein-Geltink J, Forte T, Lockwood G, Bryant H.

Curr Oncol. 2013 Aug;20(4):227-9. doi: 10.3747/co.20.1436. No abstract available.

38.

Examining the use of salpingectomy with hysterectomy in Canada.

Sandoval C, Fung-Kee-Fung M, Gilks B, Murphy KJ, Rahal R, Bryant H.

Curr Oncol. 2013 Jun;20(3):173-5. doi: 10.3747/co.20.1560. No abstract available.

39.

New chart review data validate administrative data-based indicator for guideline-recommended treatment of locally advanced non-small-cell lung cancer and shed light on reasons for non-referral and non-treatment.

Klein-Geltink J, Forte T, Rahal R, Darling G, Cheung W, Alvi R, Noonan G, Russell C, Vriends K, Niu J, Lockwood G, Bryant H.

Curr Oncol. 2013 Apr;20(2):118-20. doi: 10.3747/co.20.1351. No abstract available.

40.

Indicator measures er/pr and her2 testing among women with invasive breast cancer.

Sandoval C, Rahal R, Forte T, Klein-Geltink J, He D, Bryant H.

Curr Oncol. 2013 Feb;20(1):62-3. doi: 10.3747/co.20.1290. No abstract available.

41.

A retrospective chart review validates indicator results and provides insight into reasons for non-concordance with evidence-based guidelines.

Klein-Geltink J, Forte T, Rahal R, Niu J, He D, Lockwood G, Cheung W, Darling G, Bryant H.

Curr Oncol. 2012 Dec;19(6):329-31. doi: 10.3747/co.19.1224. No abstract available.

42.

[Effectiveness of a quality control program in mammography for the Brazilian National Health System].

Corrêa Rda S, Freitas-Junior R, Peixoto JE, Rodrigues DC, Lemos ME, Dias CM, Ferreira Rde S, Rahal RM.

Rev Saude Publica. 2012 Oct;46(5):769-76. Portuguese.

43.

Conditional survival in Canada: adjusting patient prognosis over time.

Bryant H, Lockwood G, Rahal R, Ellison L.

Curr Oncol. 2012 Aug;19(4):222-4. doi: 10.3747/co.19.1148. No abstract available.

44.

Recently published indicators allow for comparison of radiation treatment rates relative to evidence-based guidelines for rectal cancer.

Rahal R, Forte T, Lockwood G, Klein-Geltink J, Bryant H.

Curr Oncol. 2012 Jun;19(3):175-6. doi: 10.3747/co.19.1065. No abstract available.

45.

Nanoroses of nickel oxides: synthesis, electron tomography study, and application in CO oxidation and energy storage.

Fihri A, Sougrat R, Rakhi RB, Rahal R, Cha D, Hedhili MN, Bouhrara M, Alshareef HN, Polshettiwar V.

ChemSusChem. 2012 Jul;5(7):1241-8. doi: 10.1002/cssc.201100620. Epub 2012 Apr 11.

PMID:
22492587
46.

Mammary duct ectasia: an overview.

Rahal RM, de Freitas-Júnior R, Carlos da Cunha L, Moreira MA, Rosa VD, Conde DM.

Breast J. 2011 Nov-Dec;17(6):694-5. doi: 10.1111/j.1524-4741.2011.01166.x. Epub 2011 Oct 17. No abstract available.

PMID:
21999642
47.

Internalisation of hybrid titanium dioxide/para-amino benzoic acid nanoparticles in human dendritic cells did not induce toxicity and changes in their functions.

Migdal C, Rahal R, Rubod A, Callejon S, Colomb E, Atrux-Tallau N, Haftek M, Vincent C, Serres M, Daniele S.

Toxicol Lett. 2010 Nov 10;199(1):34-42. doi: 10.1016/j.toxlet.2010.07.017. Epub 2010 Aug 10.

PMID:
20699112
48.

Incidence trend for breast cancer among young women in Goiânia, Brazil.

Freitas R Jr, Freitas NM, Curado MP, Martins E, Silva CM, Rahal RM, Queiroz GS.

Sao Paulo Med J. 2010;128(2):81-4.

49.

Regulation of Spo12 phosphorylation and its essential role in the FEAR network.

Tomson BN, Rahal R, Reiser V, Monje-Casas F, Mekhail K, Moazed D, Amon A.

Curr Biol. 2009 Mar 24;19(6):449-60. doi: 10.1016/j.cub.2009.02.024. Epub 2009 Mar 5.

50.

The Polo-like kinase Cdc5 interacts with FEAR network components and Cdc14.

Rahal R, Amon A.

Cell Cycle. 2008 Oct;7(20):3262-72. Epub 2008 Oct 25.

Supplemental Content

Support Center